Despite the increased risk of thrombosis in cancer patients compared with healthy individuals, mechanisms that regulate cancer-induced hypercoagulation are incompletely understood. The aimof this study was to investigatewhether cell-specific hypoxia-inducible factor (HIF) 1aregulates cancer-Associated hypercoagulation, using in vitro clotting assays and in vivo cancer models. In mouse lung and mammary tumor cells, hypoxia led to increases in cell adhesion, clotting, and fibrin deposition; these increases were eliminated in HIF1a null cells. Increased levels of HIF1a were also associated with increased tissue factor expression in human breast tumor samples. Conversely, deletion of endothelial (but not myeloid) cell-specific HIF1a doubled pulmonary fibrin deposition, and trebled thrombus formation compared with wildtype littermates in tumor-bearing mice. Our data suggest that tumor and endothelial cell-specific HIF1a may have opposing roles in cancer-Associated coagulation and thrombosis. Off-Target effects of manipulating the HIF1 axis in cancer patients should be carefully considered when managing thrombotic complications.
ASJC Scopus subject areas
- Cell Biology